1-17 of 17
Authors: M Unverdorben
Journal Article
Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Global registry Free
European Heart Journal, Volume 45, Issue Supplement_1, October 2024, ehae666.604, https://doi.org/10.1093/eurheartj/ehae666.604
Published: 28 October 2024
Journal Article
Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk: insights from the ETNA-AF-China 1-year follow-up Free
European Heart Journal, Volume 45, Issue Supplement_1, October 2024, ehae666.608, https://doi.org/10.1093/eurheartj/ehae666.608
Published: 28 October 2024
Journal Article
Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program Free
European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.334, https://doi.org/10.1093/eurheartj/ehad655.334
Published: 09 November 2023
Journal Article
Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry Free
European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.333, https://doi.org/10.1093/eurheartj/ehad655.333
Published: 09 November 2023
Journal Article
Clinical outcomes in patients receiving oral anticoagulation stratified by the presence of dose reduction criteria and older age: a subanalysis of ENVISAGE-TAVI AF Free
European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.1677, https://doi.org/10.1093/eurheartj/ehad655.1677
Published: 09 November 2023
Journal Article
The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure Free
European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.2700, https://doi.org/10.1093/eurheartj/ehac544.2700
Published: 03 October 2022
Journal Article
Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme Free
European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.2702, https://doi.org/10.1093/eurheartj/ehac544.2702
Published: 03 October 2022
Journal Article
Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme Free
European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.2701, https://doi.org/10.1093/eurheartj/ehac544.2701
Published: 03 October 2022
Journal Article
Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program Free
European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2980, https://doi.org/10.1093/eurheartj/ehab724.2980
Published: 14 October 2021
Journal Article
Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program Free
European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.2979, https://doi.org/10.1093/eurheartj/ehab724.2979
Published: 14 October 2021
Journal Article
Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry Free
European Heart Journal, Volume 42, Issue Supplement_1, October 2021, ehab724.0556, https://doi.org/10.1093/eurheartj/ehab724.0556
Published: 14 October 2021
Journal Article
Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study Free
European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.0401, https://doi.org/10.1093/ehjci/ehaa946.0401
Published: 25 November 2020
Journal Article
Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS) Free
European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.0657, https://doi.org/10.1093/ehjci/ehaa946.0657
Published: 25 November 2020
Journal Article
Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program Free
European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.0663, https://doi.org/10.1093/ehjci/ehaa946.0663
Published: 25 November 2020
Journal Article
P4785Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program Get access
European Heart Journal, Volume 40, Issue Supplement_1, October 2019, ehz745.1161, https://doi.org/10.1093/eurheartj/ehz745.1161
Published: 21 October 2019
Journal Article
P4788One-year outcomes of elderly patients with atrial fibrillation: snapshot data from the global noninterventional program on edoxaban treatment in routine clinical practice in atrial fibrillation Get access
European Heart Journal, Volume 40, Issue Supplement_1, October 2019, ehz745.1164, https://doi.org/10.1093/eurheartj/ehz745.1164
Published: 21 October 2019
Journal Article
Adrenal carcinoma with intravenous extension into the tricuspid valvular plane in a patient with patent foramen ovale Get access
European Heart Journal, Volume 15, Issue 5, May 1994, Pages 708–709, https://doi.org/10.1093/oxfordjournals.eurheartj.a060572
Published: 01 May 1994
